Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus (NASDAQ:TEM) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Founder and CEO Eric Lefkofsky is scheduled for a fireside chat at 2:00 p.m. ET on Monday, June 8, which will be accessible via a live webcast for investors and stakeholders.
Tempus (NASDAQ:TEM), Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center launched the IMS Open-Source Consortium to advance digital pathology. The group will develop an open-source image management platform and viewer, seeded by Tempus open-sourcing the clinical-grade Paige IMS, FullFocus viewer, FullFolio case manager, and AI modules.
Tempus (NASDAQ:TEM) announced upcoming clinical availability of xH, a whole-genome sequencing assay for hematologic malignancies, including AML, MDS, MPN, and MDS/MPN. The test uses NGS on blood and bone marrow to detect actionable oncologic targets.
Analytical validation on 235 specimens showed 97.29% PPA for SNVs/indels, 92.86% for SVs, and 93.43% for CNAs, with PPV of 98.97% for SNVs/indels and 100% for SVs. ASCO 2026 data in an MDS cohort showed >99% sensitivity and 40% more clinically relevant genomic findings versus traditional techniques. xH is expected to be commercially orderable later this year.
Tempus AI (NASDAQ:TEM) launched the next-generation of Lens, an agentic AI platform for oncology drug development and research. The platform connects Tempus multimodal data, AI tooling and computing to generate evidence faster.
Lens uses over a decade of longitudinal real-world data, more than 8.5 million de-identified patient records, oncology foundation models, and validated AI agents, and is already used by 19 of the top 20 largest biopharma companies.
Tempus (NASDAQ:TEM) launched the national PRECISION Challenge to accelerate oncology breakthroughs using its multimodal foundation model. The program offers selected research teams structured access to Tempus’ de-identified clinical, molecular, and imaging data, AI models, and compute via Lens Workspaces, plus staged grants of $25,000 and $75,000.
Tempus AI (NASDAQ:TEM) launched Tempus Preview, an AI-powered application that provides preliminary genomic insights within about 24 hours of tissue receipt. It is designed to bridge the time gap between ordering a diagnostic test and receiving final sequencing results in precision oncology.
At launch, Tempus Preview targets high-impact biomarkers, including MSI-H in several solid tumors, EGFR mutations in NSCLC, and rare FGFR fusions in hepatobiliary and bladder cancers, using the Paige Predict AI model validated for clinical use.
Tempus AI (NASDAQ:TEM) reported initial results from its multimodal foundation models for oncology insight generation, built on more than 500 petabytes of de-identified clinical, genomic, imaging, and transcriptomic data.
The latest transformer-based patient trajectory model, trained on 2.5 million longitudinal records, showed prognostic value in NSCLC and potential utility for clinical trial design and drug development.
Tempus (NASDAQ:TEM) received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform, a 648-gene tissue-based assay for comprehensive genomic profiling of solid tumors.
The approval enables migration of Tempus’ entire DNA solid tumor portfolio to FDA-approved assays under unified ADLT pricing, with an estimated $200 ASP benefit from 2027, according to the company.
Tempus AI (NASDAQ:TEM) announced a major expansion of its AI-enabled Next platform to deliver real-time clinical intelligence and close care gaps in oncology.
The platform now supports six new clinical scenarios and is backed by a multi-center eNSCLC study showing higher biomarker testing and guideline-concordant therapy.
Tempus AI (NASDAQ: TEM) announced a major upgrade to its smart physician platform Tempus Hub on May 27, 2026. The platform now embeds a next-generation, agentic generative AI co-pilot directly into Hub to support oncology clinical workflows at the point of care.
Key features include proactive AI genomic patient insights, instant generation of patient-specific documentation using Tempus data, and future plans to connect genomics results with Tempus’ longitudinal patient registry and HIE data. The upgrade builds on Tempus’ Edge, Locker, and Air infrastructure to link AI with real-time healthcare data.